Key facts
- Atlas Endoscopy’s last known valuation is $12.3M (Sep 2025).
- It has raised $1.9M; the latest was Early Stage VC ($1.1M) in Sep 2025.
- Notable investors include Vanderbilt University, Deepbridge Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Atlas Endoscopy
- ·The full record, as it builds
Funding rounds
No funding rounds for Atlas Endoscopy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atlas Endoscopy
Developer of a robotic colonoscopy system designed to democratize access to colonoscopy procedures. The company develops advanced endoscopic technology that offers a higher standard of care for patients and precision tools for endoscopists, enabling clients to enhance healthcare capacity and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Leeds, United Kingdom
- Founded
- 2021
- Employees
- 17
- Website
- atlasendoscopy.org/
- Ownership
- Privately Held (backing)
Atlas Endoscopy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atlas Endoscopy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atlas Endoscopy in its N-PORT filings yet. We sweep new filings monthly.